Agilent stock rises on EU approval for cancer diagnostic

Agilent Technologies shares rose 3.2% in premarket trading after the company received European Union certification (CE mark) for its PD-L1 IHC 22C3 pharmDx companion diagnostic for ovarian cancer. The approval enables testing of PD-L1 expression in epithelial ovarian, fallopian tube, or primary peritoneal carcinoma patients and may identify those eligible for Merck’s KEYTRUDA (pembrolizumab), supported by the KEYNOTE-B96/ENGOT-ov65 trial. Agilent says this is the eighth CE-marked indication for PD-L1 IHC 22C3 pharmDx in the EU, while the company reported $6.95B revenue in FY2025.

Analysis

This is more meaningful for Agilent's diagnostics franchise than for near-term EPS. The economic value is in locking another pathology workflow into a proprietary assay plus recurring consumables, which incrementally improves mix and defensibility even if the absolute revenue contribution is small versus the core business. In other words, the market should view this as another proof point that A can keep monetizing its installed base through companion diagnostics rather than a discrete demand spike.

For Merck, the strategic value is lifecycle protection: every additional validated biomarker pathway helps sustain KEYTRUDA’s relevance as competition intensifies and newer immuno-oncology agents chip away at share. But ovarian cancer is not a needle-mover for the company, so any benefit likely shows up as marginally better international penetration and protocol standardization rather than a material revision to the PD-1 growth curve. The second-order winner may be the pathology ecosystem broadly, as this reinforces the trend toward more assay-heavy, centralized testing and away from less-specific treatment selection.

The market risk is over-interpreting a regulatory certification as an earnings event. Reimbursement, lab adoption, and actual patient funnel conversion are the real bottlenecks; if EU uptake is slow, this fades back into a portfolio of small, sticky wins. The contrarian view is that this may be underappreciated as a long-duration annuity builder for Agilent’s diagnostics mix, but overdone as a catalyst for MRK. Falsifiers: no visible improvement in A’s diagnostics growth/margin mix over the next 2-3 quarters, or no evidence that the ovarian indication meaningfully increases KEYTRUDA testing volumes in Europe within 6-12 months.

Key Decisions for Investors

• Buy A on any post-news fade, sized as a quality compounder position, with a 6-18 month horizon. Thesis: recurring CDx pull-through and stronger diagnostics mix matter more than the headline event; risk/reward is favorable if the stock gives back the opening pop.
• Do not chase MRK on this headline. Treat it as incremental lifecycle support only; if already long, keep it, but this is not enough to justify adding risk ahead of broader KEYTRUDA growth data.
• Pair trade idea: long A / short a diagnostics peer basket or healthcare tools ETF strength if the stock gap-up implies a step-change in fundamentals. This is only attractive if A rallies materially more than the implied earnings contribution; otherwise skip the trade.
• Set a watch item on EU reimbursement and lab adoption over the next 1-2 quarters. If there is no evidence of assay volume acceleration, fade the thesis and reduce any tactical long in A.